Dutch biotechnology company, Crucell N.V. has entered into a co-exclusive PER.C6 and Advac technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth.
Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.
Crucell's AdVac technology is a recombinant vector technology used to develop novel adenoviral-based products.
PER.C6 technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.
Crucell N.V. is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza.